Small Cap Feast

15th February 2024

Dish of the day
No Joiners today
Off the menu
No leavers today


Dish Of The Day:


Admissions: 



Delistings:




Whats baking in the oven?

Potential Initial Public Offerings:

12 January: The London Tunnels PLC announces its intention to seek Admission to the Standard Segment of the Official List and to trading on the Main Market of the LSE. The Company plans to restore, adaptively reuse and bring back to life the Kingsway Exchange Tunnels in Central London, originally built in the early 1940’s, and designed to shelter people during the London Blitz. The Company has successfully raised approximately £10m from investors and aims to admit its Ordinary Shares at a price of £2.00 per share to the Main Market. The Company is expected to have a market capitalisation of approximately £123m on Admission. Delayed: Expected Admission was before the end of January 2024.


Reverse Takeovers:

30 January: Location Sciences Group Plc is proposing to acquire the entire issued share capital of Sorted Holdings Limited (Sorted) for a nominal consideration of £1.00 (Acquisition). Sorted operates a software-as-a-service (SaaS) business model providing delivery experience software which serves ecommerce retailers - from large, global enterprises to smaller, independent start-ups. Pursuant to Rule 14 of the AIM Rules for Companies, the Acquisition constitutes a reverse takeover. Capital to be raised on Admission is approximately £2.0m via a subscription for new Ordinary Shares. Anticipated market capitalisation on Admission is approximately £6.68m. Expected AIM Admission date is 19 February 2024.


Change of Market:


Banquet Buffet

CMO Group 23.5p £16.9m (CMO.L)

The UK's largest online only retailer of building materials and products has expanded its offering with the launch of Landscaping Superstore. The new superstore provides DIY and professional trade customers with quick and convenient access to over 6,000 different products for all aspects of garden design and maintenance. The new Landscaping Superstore becomes CMO's ninth online store, following the successful introduction of gardening and landscaping ranges to CMO's existing Drainage Superstore.  

Crossword Cybersecurity* 5.5p £5.2m (CCS.L)

The cybersecurity solutions Company focused on cyber strategy and risk announces the signing of a Partnership Agreement with TD SYNNEX (NYSE: SNX), a global leader in IT solutions and distribution. Crossword's Trillion platform will become available through TD SYNNEX's extensive community of small and medium-sized resellers across Europe. Crossword and TD SYNNEX will also be working in collaboration with ongoing onboarding and support services across the UK and Europe. Trillion is a Threat Intelligence platform that continuously tracks, correlates and analyses billions of stolen user credentials and threat actor exchanges. The platform provides the ideal solution for MSPs and partners looking to protect end user data at scale.

DSW Capital 49p £10.7m (DSW.L)

The profitable, mid-market, challenger professional services licence network and owner of the Dow Schofield Watts brand announces a  trading update for the year ending 31 March 2024 (FY24). Network revenue for January was substantially below expectations and in February, the Group has been advised of both slippage to some previously anticipated deal revenue and, to a lesser extent, deal aborts. The Group now anticipates FY24 adjusted pre-tax profit to be in the range of £0.6m to £0.7m. The Group remains profitable and maintains a healthy cash balance of £2.7m at 31 January 2024, following the £0.2m dividend payment in that month. 

Poolbeg Pharma*  10.35p  £51.8m (POLB.L)

The biopharmaceutical Company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that Cathal Friel, Co-Founder, substantial shareholder, and currently Non-Executive Chairman, is assuming the role of Executive Chairman effective immediately. Cathal will continue to work closely with CEO Jeremy Skillington and the now expanded leadership team, several of whom have recently joined from Amryt Pharma. Meanwhile, the Remuneration Committee has approved the adoption of an Employee Performance Incentive Plan for key senior management, to align medium and long term objectives with those of shareholders and to encourage retention.

Premier African Minerals 0.2875p £77.4m (PREM.L)

The mining Company that explores, evaluates and develops mineral properties focused mainly in tungsten, lithium and tantalum, nickel and rare earth elements, announce a subscription to raise £2.475m on before expenses at an issue price of 0.275 pence per new ordinary share for the Zulu Lithium and Tantalum Project (Zulu). The proceeds will be used specifically for direct operating expenses at Zulu, including final payments related to the thickener purchase and installation; final payments related to the ball mill and associated hydrosizers, transport and installation; plant operating spares and reagents; mining cost and operating expenses including diesel.

Quadrise 2.105p  £32.9m (QED.L)

The supplier of innovative energy solutions for a cleaner planet announces the signature of a Project Development Agreement with renewable biofuels specialists, BTG Bioliquids BV (BTL) and Euthenia Energy Group Limited (Euthenia). As announced on 8 June 2023, Quadrise and BTL entered into a Joint Development Agreement  to investigate the use of BTL's fast pyrolysis bio-oil (FPBO) as a potential cost-effective renewable feedstock for Quadrise's bioMSAR solution. Building on this success, Quadrise and BTL have signed the PDA with Euthenia, who will process ligno-cellulosic biomass feedstock at their facilities in Spain using BTL's FPBO and fractionation technologies, with the extracted sugars blended into Pyrolytic bioMSAR to provide sustainable marine fuel.

Renalytix 31.5p £31.5m (RENX.L)

The artificial intelligence-enabled in vitro diagnostics Company reports financial results for the six months ended December 31, 2023. Revenue was $1.2m related to sales of KidneyIntelX, down by $0.8m year-on-year mainly due to a $1.0m decrease in billable testing volumes as a result of the transition to a commercial billing structure. Administrative expenses for the six months ended December 31, 2023 were $18.4m, compared to $22.4m for the six months ended December 31, 2022. Net loss was $19.3m during the period, compared to a net loss of $22.6m for the six months ended December 31, 2022. Cash and cash equivalents totaled $5.6m as of December 31, 2023.

Sareum* 42.5p £29.9m (SAR.L)

The clinical-stage biotechnology Company developing next generation kinase inhibitors for autoimmune disease and cancer, announces the completion of the single ascending dose (SAD) part and the food effect study of its Phase 1a clinical trial for the lead programme SDC-1801. The multiple ascending dose study is ongoing and full safety data from the Phase 1a clinical trial are expected to be available during the first half of 2024. If the results are satisfactory and subject to financing, regulatory requirements, and recruitment preparations, the Company plans to initiate a Phase 1b clinical study. The goal is to recruit up to 24 psoriasis patients, with the study expected to be completed by the end of 2024.

Tortilla Mexican Grill 39p £15.1m (MEX.L)

The UK's largest fast-casual Mexican restaurant brand has confirmed Uber Eats and Just Eat as its delivery partners, following a review of the brand's delivery strategy to strengthen the relationship between fewer partners. The Group delivered more than 1.5m mains [we assume main meals] across Uber Eats, Just Eat and Deliveroo in 2023 but delivery commission charges have challenged margin performance. Uber Eats UK had the highest order growth in the industry in 2023, with Gross Bookings up nearly 20% year-over-year.

Water Intelligence 380p  £66.0m (WATR.L)

The multinational provider of precision, minimally-invasive leak detection and remediation solutions for both potable and non-potable water provides a trading update for the year ended 31 December 2023. The Group is trading in-line with market expectations and has started 2024 well it said. FY23 revenue grew 7% to $76.0m (FY22: $71.3m). Statutory profit before tax increased 13% to $6.2m (FY22: $5.5m).  At 31 December, the Group had cash of $15.8m and the total debt (including deferred payments for acquisitions) of $22.8m. The Group's capability to deploy capital is expected to increase during 2024. In December 2023, the Group announced that it had increased its acquisition line of credit with M&T Bank by $5m.  

.

15 February 2024
*A corporate client of Hybridan LLP or retained by Hybridan LLP for certain services
** Arranged by most recent first
*** Alphabetically arranged

STAY INFORMED

Our daily digest of news from UK listed Small and Mid caps straight to your Inbox.

Disclaimer

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.

© Copyright 2024 - Hybridan | Website by Boxed Up Media
First Visit
bookcrossmenu linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram